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In vitro models of smoking-related diseases and disease processes are valuable for mechanistic
understanding and assessment of novel tobacco products. Many laboratories have used particulate phase
or aqueous extracts of cigarette smoke as an exposure system for in vitro models. However, this may not
be the most relevant method of exposing cells to smoke and its toxicants.
Here we have examined the use of human serum as an exposure system. Cultured human umbilical
vein endothelial cells were exposed in vitro to sera (50% dilution in culture media) from human
volunteers (9 smokers; 10 non-smokers) for 20 h.
Statistically-signiﬁcant differential changes were detected in endothelial migration in an endothelial
damage repair model, such that smokers’ sera had an inhibitory effect on migration compared with sera
from non-smokers (p < 0.05). We further observed several statistically-signiﬁcant differences in cardio-
vascular disease (CVD)-relevant gene expression between cells exposed to smokers’ and non-smokers’
sera, as well as differences in levels of cytokines secreted from endothelial cells.
Our data demonstrate that human sera from smokers and non-smokers can differentially regulate
endothelial function. We suggest that human serum provides a relevant exposure medium for in vitro
studies assessing the impact of cigarette smoking on CVD risk potential.
 2015 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction vessels and regulate vascular function. In a healthy individual andAtherosclerotic cardiovascular disease (CVD) is a major cause of
mortality in the Western world. The deﬁning characteristic of this
disease is the formation of atherosclerotic lesions or plaques, which
occlude blood vessels and disrupt blood ﬂow. This leads to acute
manifestations such as myocardial infarction and stroke, in which
tissue oxygen and nutrient supply are severely compromised.
Atherosclerotic plaques are vulnerable to rupturing, which gives
rise to a thrombus that can travel away from the initial plaque site
to occlude blood vessels elsewhere in the body (Libby et al., 2002;
Rader and Daugherty, 2008; Ross, 1999). Atherosclerosis was ini-
tially considered to be a simple disease involving arterial lipid accu-
mulation. However, it is now known to involve a cascade of
inﬂammatory processes (Ross, 1999; Libby et al., 2002; Rader and
Daugherty, 2008) initiated by damage to the endothelium (Hajjar
et al., 1981; Hadi et al., 2005), a monolayer of cells that line bloodprior to the onset of CVD, the endothelium plays a homeostatic role
in maintaining vascular tone and blood ﬂow (Hadi et al., 2005). In
the early stages of CVD development, endothelial damage and dys-
function trigger a chronic inﬂammatory process in the vessel wall,
involving several other cell types, including vascular smooth mus-
cle cells, monocytes (that differentiate into tissue macrophages
and subsequently foam cells) and platelets (Gimbrone et al., 2000;
Galkina and Ley, 2007; Packard and Libby, 2008).
Cigarette smoking has long been recognised to cause gross
structural damage to the endothelium and endothelial dysfunction
(Boutet et al., 1980; Zimmerman and McGeachie, 1987; Blann and
McCollum, 1993; Newby et al., 1999; Bernhard et al., 2003).
Although the cellular and molecular mechanisms underlying the
effects of cigarette smoke on the endothelium are yet to be fully
deﬁned, this phenomenon has the potential for a major involve-
ment in initiating atherogenesis. Based on the evidence that
smoking-related diseases are dose-related and epidemiological
studies have shown a reduction in the risk of smoking-related
diseases following smoking cessation, the US Institute of Medicine
(IOM) reported in 2001 that it might be possible to reduce
smoking-related risks by developing reduced-exposure products
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result in the substantial reduction in exposure to one or more
tobacco toxicants and (2), if a risk reduction claim is made, prod-
ucts that can reasonably be expected to reduce the risk of one or
more speciﬁc diseases or other adverse health effects (Stratton
et al., 2001). More recently, the IOM published a further report
after a request from the US Food and Drug Administration, which
focused on scientiﬁc studies to assess modiﬁed risk tobacco prod-
ucts (Committee on Scientiﬁc Standards for Studies on Modiﬁed
Risk Tobacco Products, Institute of Medicine, 2012). Together,
these reports propose that data from disease-relevant in vitromod-
els are useful in the assessment of the biological effects of reduced-
toxicant cigarettes and may contribute to product evaluation
(Stratton et al., 2001; Committee on Scientiﬁc Standards for
Studies on Modiﬁed Risk Tobacco Products, Institute of Medicine,
2012). To this end, we have recently demonstrated that an
in vitro CVD-related biological response was modiﬁed when
endothelial cells were exposed to smoke extracts from cigarettes
that contained different levels of toxicants (Fearon et al., 2012).
Cigarette smoke is a complex and dynamic mixture of more
than 6000 identiﬁed chemical constituents (Rodgman and
Perfetti, 2013) in both its particulate and vapour phases and some
of these chemicals have been identiﬁed as potential contributors to
the toxicity of cigarette smoke. Studies examining the effects of
cigarette smoke on in vitro CVDmodels commonly use smoke engi-
nes and appropriate trapping systems to capture particulate matter
or aqueous extracts (containing water-soluble particulate and
gases) to be used as exposure agents (Fearon et al., 2013).
However, it has been questioned whether these exposure agents
are a relevant model for the exposure of the endothelium, and
other cells of the cardiovascular system to smoke constituents
and toxicants (Fearon et al., 2013). For example cells within a smo-
kers’ cardiovascular system may be exposed to particulate matter
at a lower level than that replicated by in vitro models.
Furthermore, the biological relevance of using smoke extracts has
been questioned because in vitro models often lack metabolic
capacity, meaning that cells are exposed to smoke toxicants them-
selves but not necessarily to either active or inactive metabolites
which would be found in vivo. Since isolated serum would contain
relevant soluble toxicants and their metabolites, which are absent
in smoke extracts, we investigated the use of human serum as an
exposure method. This was achieved by exposing cultured
endothelial cells in vitro to sera obtained from healthy smokers
and non-smokers prior to measuring cardiovascular disease-
relevant endpoints.
2. Methods
2.1. Human serum samples
Serum samples were obtained from 20 healthy male donors (10
smokers and 10 non-smokers), provided by Asterand (Detroit, MI,
USA). Inclusion and exclusion criteria are listed in the
Supplementary Information Appendix 1. The study was performed
in accordance with the requirements of the UK Human Tissue
Authority. Sample collection was approved by an Institutional
Review Board and written informed consent was obtained from
all donors. Each collected serum sample consisted of eight 1 ml ali-
quots. Due to sample haemolysis, serum from one smoking donor
(ID 125662) was not included in the data analysis.
2.2. Cell culture
Human umbilical vein endothelial cells (HUVECs; Lifeline
Cell Technology, California, USA) were maintained at 37 C in a
5% CO2 humidiﬁed atmosphere. Cells were cultured in VascuLifeVEGF cell culture media (Lifeline Cell Technology) supplemented
with vascular endothelial growth factor (5 ng/ml), epidermal
growth factor (5 ng/ml), basic ﬁbroblast growth factor
(5 ng/ml), insulin-like growth factor 1 (15 ng/ml), ascorbic acid
(50 lg/ml), L-glutamine (10 mM), hydrocortisone hemisuccinate
(1 lg/ml), heparin sulphate (0.75 units/ml) and foetal bovine
serum (FBS) (2%). After thawing, cells were grown for 3 days before
passaging by trypsinisation, centrifugation and resuspension. Cells
were then seeded into new ﬂasks, or into 24-well plates for migra-
tion assays. Cells plated in ﬂasks were subsequently passaged the
following day and seeded into 24-well plates. Cells were only used
up to passage 3.2.3. Endothelial scratch wound (migration) assay
The effects of human sera on the migration of HUVECs were
assessed in a scratch wound assay. Cells were seeded in 24 well
ImageLock plates (Essen Instruments, Ann Arbor, MI, USA)
24–48 h prior to experimentation and allowed to grow to
conﬂuency. On the experimental day, conﬂuency was determined
by scanning each well using the IncuCyte imaging apparatus
(Essen Instruments); only when all wells were fully conﬂuent were
experiments performed. After conﬁrming conﬂuency, the culture
media was changed from one containing 2% FBS, to media contain-
ing a nominal amount of FBS (0.1%). Six hours later, a scratch
wound was made in each well using the WoundMaker apparatus
(Essen Instruments). Sterile 10 ll pipette tips were attached to
the WoundMaker and lowered into four wells. The plate was
moved backwards and forwards three times to create scratch
wounds. This procedure was repeated for a further two columns
of four wells before the tips were changed to scratch the remaining
three columns. After wounding, the media was replaced with
media containing 0.1% FBS and 50% human donor serum. To com-
pare the effects of sera from smokers and non-smokers on
endothelial migration, cells were exposed to serum from each
donor in different wells. Scratch assays were performed twice at
different cell passage numbers for each serum sample, with four
experimental repeats in each case. In each assay, three smokers’
and three non-smokers’ sera samples were analysed on a single
ImageLock plate. Numerical data were obtained by measuring
the scratch wound width at each hourly timepoint over a period
of up to 24 h. The decreasing wound width over this time was used
to calculate an average endothelial migration rate. Data from the
four experimental repeats were averaged and any images that
were out of focus or did not include both sides of the wound were
discarded.2.4. Endothelial cell protein expression
We compared the amount of protein secreted from endothelial
cells that had been exposed to sera from smokers or non-smokers.
The proteins examined were representative proteins involved in
CVD or inﬂammation and included interleukin 6 (IL-6), interleukin
8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and inter-
cellular adhesion molecule-1 (ICAM-1). Prior to exposing endothe-
lial cells to the sera, the background levels of these proteins in the
sera itself (1:1 diluted in culture media) were measured using
MSD protein assays. Following serum exposure in the migration
assay, media samples from each well were removed and analysed
using MSD protein assays. To determine the level of protein
secreted by the endothelial cells, the background protein level in
the sera was subtracted from the level measured in the HUVEC
culture media following sera exposure.
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IL-6, IL-8 and MCP-1 were individually assessed by electro-
chemiluminescence using singleplex MSD assays (Meso Scale
Discovery, MD, USA). MSD Diluent 2 (25 ll) was added to each
of the wells. The plate was sealed and incubated for 30 min with
agitation, after which, 25 ll calibrator (0–10 ng/ml) or sample
solution was added to the plate. For analysis of ICAM-1, 150 ll
5% MSD Blocker A Solution was added to all wells of the 96-well
plate. The plate was sealed and incubated for one hour with agita-
tion. Each well was washed three times with wash buffer before
the addition of 40 ll MSD Diluent 15 to each well. After which,
10 ll calibrator (0–1 mg/ml in MSD Diluent 15) or sample
(diluted 1:200 in 1% MSD Blocker A Solution) was added. All
plates were then sealed and incubated for 2 h with vigorous agita-
tion. Plates were washed three times with 0.05% (v/v) phosphate
buffered saline-polyethylene sorbitan monolaurate (PBS-Tween-
20) before the addition of 25 ll SULFO-TAG anti-human IL-6,
anti-human IL-8, anti-human MCP-1 or anti-human ICAM-1 detec-
tion antibody provided by the supplier, at 1 lg/ml. The plate was
re-sealed and incubated for 2 h with vigorous shaking. Plates were
washed a further three times with wash buffer and 150 ll 2
MSD Read Buffer was added. Plates were read using a MSD
SECTOR 2400 imager and protein concentration was assessed
against a standard curve, using MSD Workbench software v3.0.
The background concentration of cytokines (IL-6, IL-8, MCP-1 and
ICAM-1) within the sera samples themselves were assessed using
the same methods and subtracted from the values obtained from
the media samples.
2.5. Endothelial cell gene expression
We examined gene expression in HUVECs treated with sera
from non-smokers versus smokers. After a 24-h treatment with
sera in the migration assay, the cells were harvested and their
genetic material subjected to TaqMan gene expression analysis
using a custom-designed plate that was designed to incorporate
several genes known to be regulated in CVD. Full details of the
28 genes examined are shown in Supplementary Table 1.
2.5.1. Endothelial cell gene (TaqMan) expression sample collection
Following completion of the HUVEC migration assay, condi-
tioned media was removed and stored for later analyses. The cells
in the assay plates were then lysed in TRIzol reagent (Life
Technologies, Paisley, Scotland). In each case, samples from four
replicate wells were pooled and stored in two aliquots per donor
at 80 C for future analysis. Chloroform (200 ll per ml of TRIzol)
was added to each of the samples, which were then shaken vigor-
ously before centrifugation for 20 min at 4 C. The aqueous layer
was transferred into a new centrifuge tube with pellet paint and
sodium acetate and mixed with 2 volumes of ethanol to precipi-
tate RNA overnight at20 C. mRNAwas pelleted by centrifugation
followed by an ethanol wash. The pellet was resuspended in DNAse
reaction master mix (Sigma Aldrich, Poole, UK) for 15 min before
addition of stop solution (Sigma). The RNA samples were heated
at 70 C and then cooled on ice.
2.5.2. TaqMan gene expression analysis
Each RNA sample was reverse transcribed using the BioRad
iScript cDNA synthesis kit (Bio-Rad Laboratories Inc., CA, USA).
The reaction mix comprised 1 lg diluted RNA, 4 ll 5 iScript buf-
fer and 1 ll iScript reverse transcriptase, made up to a ﬁnal volume
of 20 ll with nuclease-free water. After using the recommended
thermal cycler programme, the reaction was held at 4 C until
use or storage. A gene expression master mix was prepared con-
taining TaqMan gene expression mastermix (Life Technologies),
cDNA sample and water and was added across a CVD-speciﬁcTaqMan array plate (see Supplementary Table 1 for details).
Each reaction contained 400 ng of cDNA. Polymerase chain reac-
tion (PCR) was performed using the following protocol: 50 C for
2 min, 95 C for 10 min, 50 C for 2 min, 95 C for 10 min, 95 C
for 15 s, 50 cycles of 60 C for 1 min. Target gene threshold cycle
(CT) values were normalised to an average expression level of the
four housekeeping genes, small subunit 18S rRNA (18S), glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH), hypoxanthine–guanine
phosphoribosyltransferase (HPRT1) and b-glucuronidase (GUSB),
examined using Bio-Rad iQ™5 software (Bio-Rad Laboratories
Inc., CA, USA).
2.6. Statistical analysis
Migration data were analysed using mixed model analysis of
variance (ANOVA). Differences in gene and protein expression data
were examined using Student’s unpaired t-tests.
3. Results
3.1. Human sera donors
The demographic characteristics of the serum donors are shown
in Table 1. Demographics were similar between smokers and non-
smokers.
3.2. Endothelial cell migration
Following wounding, endothelial cells migrated across the
scratch at a rate that was linear over the course of the 20 h experi-
ment (Fig. 1). Over the course of the experiment, the migration rate
was lower in the endothelial cells exposed to the sera of smokers
versus the sera of non-smokers (p < 0.001, mixed model ANOVA).
At an individual timepoint for example, the mean (± SD) migration
rate 8 h after wounding was 20.4 ± 18.6 lm/h in cells exposed to
smokers’ sera, compared with 38.2 ± 10.2 lm/h in cells exposed
to non-smokers’ sera.
3.3. Endothelial cell protein expression
Background sera protein expression levels for IL-6, IL-8, ICAM-1
and MCP-1 are shown in Table 2. Statistical analysis showed no
signiﬁcant differences between protein expression levels in the
sera of smokers versus non-smokers. We observed signiﬁcant
differences in the average levels of MCP-1 and IL-6 secreted into
the media by endothelial cells that were exposed to smokers’ sera
versus non-smokers’ sera (Fig. 2). For example, the mean (± SD)
secreted MCP-1 level was signiﬁcantly lower for endothelial cells
exposed to non-smokers’ sera (4195 ± 380 pg/ml), compared with
endothelial cells exposed to smokers’ sera (6105 ± 849 pg/ml;
p < 0.05, Student’s unpaired t-test). Similarly, mean secreted IL-6
levels were also signiﬁcantly lower for endothelial cells exposed
to non-smokers’ sera (210 ± 21 pg/ml) versus smokers’ sera
(446 ± 121 pg/ml; p < 0.05, Student’s unpaired t-test). The secreted
levels of ICAM-1 and IL-8 were elevated in media from cells
exposed to smokers’ sera, however this did not reach statistical
signiﬁcance (Fig. 2).
3.4. Endothelial cell gene expression
A large degree of donor-to-donor variability was observed when
examining gene expression data, including variability in the
expression levels of the housekeeping genes, which impacted the
normalisation of the gene expression data (data not shown).
Threshold cycle (CT) values were normalised to the four house-
keeping genes examined (18S, GAPDH, HPRT1 and GUSB) and are
Table 1
Serum donor demographic characteristics.
ID Age Gender Race Height (cm) Weight (kg) BMI Smoker? CPD Ever-smoker?
125656 59 Male Caucasian 185 99 29 Y 25–30a
125657 40 Male Caucasian 170 76 26 Y 30
125658 36 Male Caucasian 173 89 30 Y 20
125659 48 Male Caucasian 180 112 35 Y Pack (20b)
125660 39 Male Caucasian c c c Y 10
125661 38 Male Caucasian 172 109 37 Y 20
125663 56 Male Caucasian 172 106 36 Y Pack (20b)
125664 38 Male Caucasian 171 76 26 Y 40
125665 41 Male Caucasian 188 91 26 Y 20
Mean ± SD 44 ± 9 – – 176 ± 7 95 ± 14 31 ± 5 – 23 ± 8 –
125666 40 Male Caucasian 180 87 27 N – N
125667 43 Male Caucasian 176 77 25 N – N
125668 43 Male Caucasian 177 82 26 N – N
125669 43 Male Caucasian 172 82 28 N – N
125670 30 Male Caucasian 178 80 25 N – N
125671 58 Male Caucasian 175 76 25 N – N
125672 44 Male Caucasian 180 102 31 N – N
125673 56 Male Caucasian 180 102 31 N – N
125674 43 Male Caucasian 178 81 26 N – N
125675 32 Male Caucasian 174 88 29 N – N
Mean ± SD 43 ± 8§ – – 177 ± 3§ 86 ± 10§ 27 ± 2§ – – –
BMI, body mass index; CPD, cigarettes per day; ID, identiﬁcation; N, no; SD, standard deviation; Y, yes.
a 27.5 CPD used to calculate mean and SD.
b Assumed 20 cigarettes per pack.
c Data unavailable (mean and SD calculated without these data).
§ p > 0.05, Student’s unpaired t-test.
Fig. 1. Comparison of the endothelial cell migration rate in an in vitro scratch
wound migration assay in cells exposed to human sera from smokers versus non-
smokers. Endothelial cell migration rate in the presence of sera from smokers or
non-smokers, as indicated. Data were averaged (mean ± SD) from studies using sera
samples from non-smokers (n = 10) and smokers (n = 9). For each sample, data were
obtained from quadruplicate wells on two separate occasions.
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pooled mixture of non-smokers’ sera.
The expression levels of the genes that reached the detection
threshold of the PCR protocol are compared between endothelialTable 2
Background protein expression levels of IL-6, IL-8, ICAM-1 and MCP-1 in sera from
smokers and non-smokers.
Protein Protein expression, mean ± SD (pg/ml)
Non-smokers’ sera (n = 10) Smokers’ sera (n = 9)
IL-6 0.3 ± 0.2 0.5 ± 0.3*
IL-8 11.8 ± 11.6 19.8 ± 17.8*
ICAM-1 0.6 ± 0.1 0.6 ± 0.1*
MCP-1 236.7 ± 48.1 274.1 ± 58.1*
ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin 6; IL-8, interleukin 8;
MCP-1, monocyte chemoattractant protein-1; SD standard deviation.
* p > 0.05, not signiﬁcantly different from levels in non-smokers’ sera, Student’s t-
test.cells exposed to sera from smokers versus non-smokers (Fig. 3).
For those genes that showed differences in expression levels
between cells exposed to smokers’ versus non-smokers’ sera, gene
expression levels relative to the expression levels in endothelial
cells exposed to sera from non-smokers are shown in Fig. 4.
Three genes (IL1-R1, TGFB1, and VEGFA) showed signiﬁcantly
greater expression levels (p < 0.05) in endothelial cells exposed to
sera from smokers compared with sera from non-smokers
(Fig. 4A). An additional two genes (CCL5 and MMP-1) showed dif-
ferential expression between endothelial cells treated with sera
from smokers versus non-smokers at levels approaching statistical
signiﬁcance (Fig. 4B). A number of genes did not reach the detec-
tion threshold within the 50 ampliﬁcation cycles used in the PCR
protocol, indicating that these genes were not expressed by the
endothelial cells or were expressed at an extremely low copy
number. These genes were CCR1, CSF2, IL-10, IL-2, IL-4, IL-5,
MMP-3, PDGFRB, PMCH, SPP1, TNF and LIF (see Supplementary
Information Appendix 2 for abbreviations).
4. Discussion
Cigarette smoking has long been associated with CVD. Studies
examining the effects of cigarette smoke extracts in disease-
relevant in vitro model systems using cells of the cardiovascular
system have further strengthened this link (Fearon et al., 2013).
However, it has been questioned whether the exposure agents
used in these types of models are sufﬁciently biologically-relevant
for the exposure of the endothelium, and other cells of the cardio-
vascular system, to smoke constituents and toxicants. Therefore,
we examined the use of human serum as an exposure agent for
models of CVD, and of inﬂammatory processes related to CVD
and other smoking-related diseases. We propose that such an
approach would be advantageous since it would expose cells to
relevant soluble toxicants and their metabolites, which are absent
in smoke extracts. The use of sera obtained from smokers and non-
smokers has been used in a previous study to examine the effects
of smoking on the production of the vasoactive molecule, nitric
oxide (Barua et al., 2003).
Fig. 2. Comparison of protein levels of MCP-1 (A), IL-6 (B), IL-8 (C), and ICAM-1 (D) secreted into culture media by endothelial cells exposed in vitro to human sera from
smokers versus non-smokers. Data (mean + SEM) are from studies using sera samples from non-smokers (n = 10) and smokers (n = 9). For each sample, data were obtained in
triplicate and on two separate occasions. ⁄p < 0.05 compared with non-smoker’s sera (Student’s unpaired t-test); NS, no signiﬁcant difference between smokers’ and non-
smokers’ sera. ICAM-1, intercellular adhesion molecule-1; IL-6, interleukin 6; IL-8, interleukin 8; MCP-1, monocyte chemoattractant protein-1; SD, standard deviation.
Fig. 3. Differential effects of sera from smokers and non-smokers on in vitro
endothelial cell gene expression. Threshold cycle (CT) values were normalised to the
four housekeeping genes examined and are expressed relative to the expression
level in cells treated with a pooled mixture of non-smokers’ sera. Data (mean + SD)
are from studies using sera samples from non-smokers (n = 10) and smokers (n = 9).
For each sample, data were obtained in triplicate. Data for genes that did not reach
the detection threshold are excluded from this plot. See Supplementary Information
Appendix 2 for abbreviations.
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CVD. A healthy endothelium possesses an innate repair capability
that ensures that damage to the endothelial lining is repaired effec-
tively, restoring blood vessel homeostasis and preventing disease
progression (Bai et al., 2010). In smokers, repair processes such
as endothelial migration are impaired and this can lead to further
events that contribute to disease progression (Fearon et al., 2012).
Using a scratch wound model of endothelial damage repair, we
have previously shown that exposure to cigarette smoke particu-
late matter inhibits endothelial migration in vitro (Fearon et al.,
2012). In this study, we observed differential effects of smokers’
and non-smokers’ sera on in vitro endothelial cell migration. The
endothelial migration rate was enhanced when exposed to humansera from non-smokers (40 lm/h) compared with the migration
rates we had previously reported (around 25–30 lm/h) (Fearon
et al., 2012). This is likely due to stimulation of migration by the
serum itself (Yue et al., 2010). In contrast, when the endothelial
cells were exposed to sera from smokers, endothelial migration
was signiﬁcantly impaired, suggesting that there may be inhibitory
factors present within the sera of smokers that impede endothelial
migration. Thus, serum may contain substances that possess the
ability to regulate endothelial migration and these substances are
perhaps speciﬁc to, or increased in the sera of smokers. One factor
that could potentially explain the differences observed between
the sera samples from the smokers and the non-smokers indepen-
dent of any changes in toxicants and/or metabolites found in the
serum, is the potential presence of nicotine and its major metabo-
lite, cotinine, in smokers’ sera. The effects of both of these com-
pounds on the cells used in this study are complex and not well
deﬁned. In fact, a previous study found that at concentrations typi-
cally found in the blood of smokers, the effects of nicotine on
endothelial migration in vitro were in fact stimulatory (Park
et al., 2008), which conﬂicts with the inhibition of migration seen
in our study. Therefore further studies may be required to deﬁne
the sensitivity of the migration assay to both nicotine and cotinine.
Our protein expression data further support the ﬁndings from
the endothelial migration assay, in that we were able to detect
increased amounts of MCP-1 and IL-6 secreted from HUVECs
exposed to smokers sera when compared to those exposed to
non-smokers’ sera. Interestingly, the protein secretion responses
observed were greatest in cells exposed to one of the donors’ sera
(data not shown), although generally speaking the responses to the
different sera were diverse across the proteins examined.
Therefore, cellular responses to smokers’ sera are potentially inﬂu-
enced by various different mechanisms that can lead to the release
of inﬂammatory mediators. The differences between protein secre-
tions from endothelial cells exposed to sera from smokers versus
non-smokers occurred in the absence of any differences between
background levels of these proteins in the sera, which is not sur-
prising because the samples were all obtained from healthy
individuals. This may indicate that it is not the levels of
Fig. 4. Comparison of gene expression levels for selected genes in endothelial cells exposed in vitro to human sera from smokers and non-smokers. Threshold cycle (CT) values
were normalised to the four housekeeping genes examined and are expressed relative to the expression level in cells treated with a mixture of non-smokers’ sera. Data
(mean + SD) are from studies using sera samples from non-smokers (n = 10) and smokers (n = 9). A, genes showing statistically signiﬁcant differences in gene expression in
endothelial cells treated for 20 h with sera from smokers or non-smokers, as indicated. B, genes altered at levels close to statistical signiﬁcance (CCL5: p = 0.08; MMP-1:
p = 0.07; Student’s unpaired t-test) in endothelial cells treated for 20 h with sera from smokers or non-smokers, as indicated. See Supplementary Information Appendix 2 for
abbreviations. ⁄p < 0.05, Student’s unpaired t-test.
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for inducing cellular responses in the in vitro assays, but instead
these are caused by other substances that are as yet unidentiﬁed,
but present in the sera of smokers. Although the identities of these
substances are unknown and require further investigation, this
ﬁnding clearly demonstrates the ability of in vitro assays to detect
differences between the sera of smokers and non-smokers.
We also investigated the expression levels of 28 genes known to
be involved in CVD in endothelial cells exposed to both smokers
and non-smokers’ sera, using a custom-designed gene array. Of
these genes, 12 were not detectable under the conditions used in
the study. However, three genes (IL1-R1, TGFB1, and VEGFA) were
expressed at levels signiﬁcantly higher in cells exposed to smokers’
sera when compared with non-smokers’ sera. Additionally, CCL5
and MMP-1 were differentially expressed at levels close to sta-
tistical signiﬁcance. Thus, in addition to functional changes in the
migration assay, we were able to observe differential changes in
gene expression in endothelial cells exposed to smokers’ and
non-smokers’ sera. These ﬁndings further support the use of
human sera as an exposure agent for in vitro models of smoking-
related CVD.
4.1. Strengths and limitations of the serum exposure approach
Although the use of serum as an exposure agent is unlikely to be
a direct replacement for exposure to cigarette smoke extracts
(Fearon et al., 2013), it does offer some advantages. The addition
of sera to culture media mimics the cellular exposure that occurs
in vivo, including exposure to toxicants that have undergone meta-
bolic activation or deactivation. Such exposure is not typically
achieved when using extracts of cigarette smoke and therefore
serum provides a more relevant exposure method that could be
used in addition to the traditional exposure methods. In fact, there
are many advantages of this approach for examining CVD-related
biological responses to cigarette smoking when compared with
more traditional approaches using machine-generated cigarettesmoke extracts. These are summarised in Table 3 and include the
exposure of cells to metabolised cigarette smoke, as well as to
other factors such as modiﬁed lipids that may be present in smo-
kers’ sera, and allowing examination of cessation effects by taking
sera from participants who have stopped smoking. This approach
may also be useful for examining biological responses in users of
other forms of tobacco or nicotine, such as heated tobacco products
or e-cigarettes. Standardised exposure methodologies have not yet
been developed and broadly accepted for these novel product
types and our approach may support comparative testing of prod-
ucts involving real-life usage.
While this study strongly supports the use of human sera as an
exposure agent for in vitro CVD models, it is not without limitation
and potential disadvantages (Table 3). The major limitation of this
study was the variability of the gene expression data, both in terms
of donor-to-donor variability as well as in the levels of the house-
keeping genes examined. To address these issues, we normalised
the gene expression data to the average expression levels of the
four housekeeping genes examined. We feel that such an approach
is suitable in this proof-of-principle study. However, for future
studies caution needs to be taken when selecting housekeeping
genes and pilot studies may be necessary in order to select the
most appropriate housekeeping genes with which to normalise
gene expression data. Furthermore, studies should be set up using
appropriate numbers of participants, such that the effects of donor-
to-donor variability are minimised and the quantitative nature of
any ﬁndings enhanced.
Further technical limitations of this study include the addition
of serum to an experimental model that is usually performed in
a serum-free culture environment (Fearon et al., 2012) and per-
forming gene and protein expression analysis in cells that were
also subjected to the scratch wound assay. While this was advan-
tageous and necessary to reduce the amount of sera required and
to facilitate the examination of multiple endpoints, it may have
affected the ﬁndings of the gene and protein expression analyses.
A further limitation of the current study concerns the participant
Table 3
Advantages and disadvantages of traditional (smoke extract) and serum exposure systems for in vitro cardiovascular disease models.
Exposure
agent
Advantages Disadvantages
Serum  Cells are exposed to metabolised cigarette smoke
 Toxicant levels in exposure agent match those seen in vivo
 Cells are also exposed to other factors that are present in serum
(e.g., modiﬁed lipid or proteins)
 Can examine differences between different groups of participant
donors (e.g., smokers and non-smokers)
 Potentially able to monitor the effects of smoking cessation
 Can monitor effects of serum from users of different types of
tobacco (e.g., snus)
 Easily adapted for novel tobacco and nicotine products without
the need to identify the appropriate smoking regimes
 Difﬁcult to control for donor variation, hence large numbers of donors
required
 Serum is only available in small volumes, which limits number of assays
that can be performed
 Procurement of serum is difﬁcult and expensive
 Difﬁcult to recruit groups of similar donors and detailed donor participant
demographic information may be missing
 Difﬁcult to control for unknown factors (e.g., use of medicines, diet, health
supplements, etc.)
 Difﬁcult to perform a dose–response study
 Serum itself may produce a response in cells
Cigarette
smoke
extract
 Easy to produce smoke extracts in the laboratory
 Large volumes of smoke extracts can be produced
 Production of smoke extracts is consistent and reproducible and
can be quality controlled
 Can produce smoke extracts from novel products with different
levels of toxicants (Fearon et al., 2013)
 Simple to perform a dose–response study
 Simple to produce smoke extracts in specialised media (e.g., when
culturing primary cells)
 Smoke extracts do not undergo metabolism, unless specialised systems
such as S9 cells are used to pre-metabolise smoke extracts
 Difﬁcult to determine biologically-relevant concentrations for use in
experiments
 Cannot accurately represent smoking cessation
 Difﬁcult to make relevant smoke extracts to examine biological responses
to extracts from other forms of tobacco or nicotine
862 K. McQuillan et al. / Toxicology in Vitro 29 (2015) 856–863donors themselves. While certain demographic information was
obtained prior to collecting sera, this information was incomplete
and more detailed information (for example concomitant med-
ication) or more rigid inclusion/exclusion criteria may help to
improve the data obtained from these types of studies.
Furthermore, although smokers were asked to refrain from smok-
ing on the day of serum collection, we have no data concerning the
time since their last cigarette, which is a parameter that could have
potentially affected the data obtained in this study. Finally, the
small volume of sera available is a limiting factor for the number
and type of assays that can be performed in such serum exposure
studies.5. Conclusions
Although we cannot draw any quantitative conclusions con-
cerning cellular responses to human sera exposure, we provide evi-
dence for the feasibility of using human serum as an exposure
system for in vitro models of CVD and other smoking-related dis-
ease processes. We propose that serum exposure represents a
more biologically-relevant method for exposing in vitro models
to the smoke components that cells are exposed to in vivo, versus
traditional exposure systems. Further studies are required to
deﬁne the sensitivity of this new approach, such as examining dif-
ferences between smokers of different intensities (e.g., those smok-
ing different numbers of cigarettes per day, smoking cigarettes
with different tar deliveries, or those with varying lifetime expo-
sures to smoke), and also in people who quit smoking.
Additionally, further work is also required to better understand
and control the variability of gene expression data obtained using
this approach. These studies would aid in deﬁning the capabilities
of the serum exposure approach in assessing the potential efﬁcacy
of novel products in reducing smoking-related disease risks. The
suitability of this approach for other types of exposure, such as
environmental exposure to toxicants, also warrants examination.Role of the funding source
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